Volociximab
Volociximab is a monoclonal antibody for the treatment of cancer. It was developed by PDL BioPharma and is currently being developed by Biogen Idec and Facet Biotech.
Mechanism of action[edit | edit source]
Volociximab works by targeting alpha5beta1, an integrin that is present in high amounts on the surface of certain types of cancer cells. By binding to this integrin, volociximab can inhibit the growth of the cancer cells.
Clinical trials[edit | edit source]
Volociximab has been tested in Phase I and Phase II for the treatment of various types of cancer, including pancreatic cancer, melanoma, and lung cancer. The results of these trials have been promising, with some patients showing a significant reduction in tumor size.
Side effects[edit | edit source]
Like all drugs, volociximab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and vomiting. Less common side effects include anemia, neutropenia, and thrombocytopenia.
Future development[edit | edit source]
The future development of volociximab will depend on the results of ongoing clinical trials. If these trials continue to show that the drug is safe and effective, it may be approved for use in the treatment of certain types of cancer.
See also[edit | edit source]
| Volociximab Resources | ||
|---|---|---|
|
| |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
